| General information | NOS score | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Author | Study design | Publish year | Country of enrolment | Neoadjuvant chemotherapy protocal | Total patients | Mean age (year) | Tumor size | Follow-up time (month) | Selection | Comparability | Outcome | Total score |
Beriwal [24] | RS | 2006 | USA | CMF or AC or CAF or ACT in unclear cycle and interval time | 153 | 52 | T I,II,III,IV | 60 | 3 | 1 | 2 | 6 |
Bonadonna [20] | CT | 2002 | Italy | Single-agent E 3Â cycles every 3Â weeks | 317 | 49 | T II,III | 60 | 3 | 2 | 2 | 7 |
Caudle [19] | RS | 2012 | USA | Anthracycline-based or taxane-based or a combination of the two | 595 | 51 | T I,II,III,IV | 64 | 3 | 1 | 2 | 6 |
Cho [22] | RS | 2013 | Korea | Unclear | 431 | 49 | T IV | 46 | 2 | 1 | 2 | 5 |
Criscitiello [28] | RCT | 2013 | Spain | Paclitaxel with HER2-targeted therapy | 455 | NA | T II,III,IV | NA | 3 | 2 | 2 | 7 |
Fastner [17] | RCT | 2014 | UAS | ED-based 3–6 cycles | 107 | 48 | T II,III | 59 | 4 | 2 | 3 | 9 |
Jimbo [21] | RS | 2015 | Japan | 4Â cycles of AC or FEC followed by weekly T | 315 | 50 | T I,II,III,IV | 61 | 3 | 1 | 2 | 6 |
Massidda [15] | CT | 2007 | Italy | PEV 6Â cycles every 2Â weeks | 40 | 48 | T IV | 84 | 3 | 1 | 2 | 6 |
McIntosh [18] | RS | 2003 | England | CVAP* 4 or 6Â cycles every 3Â weeks | 166 | 51 | T II,III,IV | 62 | 2 | 1 | 2 | 5 |
Noh [25] | RS | 2014 | Korea | AT or AC or T | 260 | 46 | T I,II,III,IV | 66 | 2 | 1 | 2 | 5 |
Rouzier [10] | RS | 2001 | France | FAC or CMF or CTF or CE 4Â cycles every 4Â weeks | 257 | 47 | T I,II,III | 93 | 3 | 1 | 2 | 6 |
Rouzier [14] | RCT | 2004 | France | Neoadjuvant epirubicin-based chemotherapy(AVCMF, FEC, FAC) 3–4 cycles at 21-day intervals or longer | 589 | 50 | T II,III | 67 | 3 | 2 | 3 | 8 |
Shen [16] | RCT | 2004 | USA | Doxorubicin-based and paclitaxel-based | 33 | 52 | T IV | 91 | 3 | 2 | 3 | 8 |
Von [27] | RCT | 2008 | Germany | TAC*6 or 8Â cycles if response. TAC*2 if response then followed by another TAC 4 or 6Â cycles, if not response then followed by NX or TAC 4Â cycles | 622 | 51.8 | T I,II,III,IV | 33 | 4 | 2 | 3 | 9 |
Walker [23] | CT | 2011 | England | AC 4Â cycles every 3Â weeks followed by weekly or every 3Â weeks docetaxel | 82 | 50 | T II,III,IV | 72 | 3 | 2 | 3 | 8 |
Yamazaki [26] | RS | 2015 | Japan | AT-based 4Â cycles | 217 | 52 | T I,II,III,IV | 84 | 3 | 1 | 2 | 6 |